Selecta Biosciences (SELB) Misses Q4 EPS by 7c

March 12, 2020 8:02 AM EDT
Get Alerts SELB Hot Sheet
Price: $0.71 --0%

EPS Growth %: +204.5%

Today's EPS Names:
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Selecta Biosciences (NASDAQ: SELB) reported Q4 EPS of ($0.28), $0.07 worse than the analyst estimate of ($0.21).

β€œ2019 was a pivotal year for Selecta. We made substantial clinical advancements, as we completed enrollment in the head-to-head COMPARE trial for our lead product candidate, SEL-212, in chronic refractory gout, and advanced our gene therapy program through strategic partnerships with AskBio. We also strengthened our organization with the addition of several key members to the executive team and welcomed a new Chairman of our Board of Directors, and completed a $70 million financing,” said Carsten Brunn, Ph.D., President and CEO of Selecta. β€œIn the coming year, we look forward to reporting topline data from the COMPARE study, commencing the Phase 3 clinical program of SEL-212, and advancing our gene therapy program into the clinic in partnership with AskBio.”

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities